Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer

This study has been completed.
Sponsor:
Collaborators:
Hoffmann-La Roche
Sanofi
AstraZeneca
Information provided by:
Finnish Breast Cancer Group
ClinicalTrials.gov Identifier:
NCT00114816
First received: June 17, 2005
Last updated: May 18, 2007
Last verified: May 2007